钆潴留:2018年美国国立卫生研究院/美国放射学会/北美放射学会钆螯合物研讨会的科研路线图
2018年2月在贝塞斯达美国国立卫生研究院召开国际会议,讨论文献与知识空白,确定优先研究方向:钆潴留是否损害人体组织功能、是否与疾病临床表现存在因果关联、儿童等脆弱人群风险是否更高。
要点
- 大环类钆对比剂的钆潴留少于线性类,但钆潴留的安全意义尚不明确。
- 少数患者将一组症状归因于钆对比剂暴露,但科学调查尚未证实该关联。
- 优先研究:钆潴留是否损害组织功能、是否与临床表现存在因果关联、儿童等脆弱人群风险是否更高。
核心结论
- 钆对比剂药理学安全性极佳,但钆在人体组织长期潴留;大环类潴留少于线性类,其安全意义未知,需优先研究组织功能损害、临床疾病因果关联及脆弱人群风险。
研究设计与样本
- 2018年2月在美国贝塞斯达美国国立卫生研究院召开的国际研讨会(美国国立卫生研究院/美国放射学会/北美放射学会),讨论钆潴留文献与知识空白并确定优先研究方向。
诊断标准与关键数值
- 大环类钆对比剂显示的钆潴留少于线性钆对比剂。
临床应用与阅片要点
- 原文未据此给出推荐。
局限性
- 钆潴留的机制和化学形式以及潴留钆物种的生物活性与临床重要性仍知之甚少。
- 少数患者将一组症状归因于钆对比剂暴露,但科学调查尚未证实这些症状与钆对比剂给药或钆潴留的关联。
- 尽管大环类钆对比剂显示的钆潴留少于线性钆对比剂,但钆潴留的安全意义未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Gadolinium-based contrast agents (GBCAs) have revolutionized MRI, enabling physicians to obtain crucial life-saving medical information that often cannot be obtained with other imaging modalities. Since initial approval in 1988, over 450 million intravenous GBCA doses have been administered worldwide, with an extremely favorable pharmacologic safety profile; however, recent information has raised new concerns over the safety of GBCAs. Mounting evidence has shown there is long-term retention of gadolinium in human tissues. Further, a small subset of patients have attributed a constellation of symptoms to GBCA exposure, although the association of these symptoms with GBCA administration or gadolinium retention has not been proven by scientific investigation. Despite evidence that macrocyclic GBCAs show less gadolinium retention than linear GBCAs, the safety implications of gadolinium retention are unknown. The mechanism and chemical forms of gadolinium retention, as well as the biologic activity and clinical importance of these retained gadolinium species, remain poorly understood and underscore the need for additional research. In February 2018, an international meeting was held in Bethesda, Md, at the National Institutes of Health to discuss the current literature and knowledge gaps about gadolinium retention, to prioritize future research initiatives to better understand this phenomenon, and to foster collaborative standardized studies. The greatest priorities are to determine (a) if gadolinium retention adversely affects the function of human tissues, (b) if retention is causally associated with short- or long-term clinical manifestations of disease, and (c) if vulnerable populations, such as children, are at greater risk for experiencing clinical disease. The purpose of the research roadmap is to highlight important information that is not known and to identify and prioritize needed research. ©RSNA, 2018 Online supplemental material is available for this article .
引用
- McDonald RJ, Levine D, Weinreb J, et al. Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates. Radiology. 2018. PMID: 30204075. doi:10.1148/radiol.2018181151
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。